Posts by: Alice Melão

News

Data from a Phase 2 clinical trial showed that combining Immune Design‘s experimental immunotherapy G100 with fractioned, low-dose radiation and Keytruda (pembrolizumab) leads to higher response rates in follicular lymphoma patients, the company announced. The randomized ... Read more

March 12, 2018March 12, 2018

Lymphoma, Breast Cancer Patients Have Higher Risk of Heart Failure, Study Shows

News

Breast cancer and lymphoma patients and survivors are 3.6 times more likely to develop heart failure than patients who did not have cancer, a study by researchers at the Mayo ... Read more

March 8, 2018March 8, 2018

Constellation’s Epigenetic Inhibitors Show Early Signs of Activity in Advanced Lymphoma Patients

News

Two investigative compounds targeting epigenetic DNA modification have shown encouraging preliminary activity in B-cell lymphoma patients, according to results from two Phase 1 trials. The inhibitors, called CPI-1205 and CPI-0610, were found to ... Read more

February 5, 2018February 5, 2018

Affimed’s AFM13 Shows High Response Rates in 2 Lymphoma Subtypes

News

AFM13, a bispecific antibody that recruits natural killer (NK) cells to the vicinity of a tumor, has shown promise in clinical trials of both Hodgkin’s lymphoma and in CD30-positive cutaneous ... Read more

January 30, 2018January 31, 2018

Gamida Recruiting Lymphoma Patients for Phase 1 Trial of Natural Killer Cell Therapy

News

Gamida Cell is enrolling participants in a Phase 1 clinical trial of its natural killer cell treatment for adults with relapsed or refractory non-Hodgkin’s lymphoma and multiple myeloma. The trial (NCT03019666) at ... Read more

January 22, 2018

Study Suggests Link Between Chernobyl and 10 Rare Eye Cancer Cases in New York City

News

The ultra-rare vitreoretinal lymphoma of 10 people in New York City could stem from the long-term effects of the 1986 Chernobyl nuclear disaster, a study suggests. The report, “A cluster of ... Read more

January 19, 2018January 19, 2018

Phase 1/2 Trial to Test Yescarta-Utomilumab Combo in Refractory Large B-cell Lymphoma

News

A new multicenter Phase 1/2 trial will evaluate an immunotherapy combination of Yescarta (axicabtagene ciloleucel) and utomilumab for the treatment of patients with refractory large B-cell lymphoma. The trial, part of a clinical ... Read more

December 18, 2017

Rhizen’s Tenalisib Receives FDA Fast Track Status for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the tenalisib (RP6530), Rhizen Pharmaceuticals‘ PI3K delta/gamma blocker, for the treatment of patients with relapsed or refractory peripheral ... Read more

December 12, 2017December 12, 2017

Immune Response to Reactive Herpes Virus Tied to Graft-versus-host Disease in Transplant Patients in Study

News

The immune system’s response to reactivated human cytomegalovirus (hCMV) infection, a form of herpes virus, has been linked to the onset of graft-versus-host disease (GVHD). The discovery, made by a ... Read more

December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more